


CLAIM AMENDMENTS

1. (Currently Amended) A compound of the formula I:



(I)

or a pharmaceutically acceptable salt thereof;

wherein X and Y are independently selected from the group consisting of O, CF₂, CH₂, and CHF;

wherein A is independently selected from the group consisting of P(O)OH, CH₂COOH, and CH(COOH)₂; CHCOOH, and C(COOH)₂;

R₂ is selected from the group consisting of H, OH, isosteres of OH, C₁-C₂₅ alkyloxy, C₆-C₁₀ aryloxy, C₃-C₈ cycloalkyloxy, C₃-C₈ cycloalkyl C₁-C₆ alkoxy, C₂-C₂₂ alkenyloxy, C₃-C₈ cycloalkenyloxy, C₇-C₃₂ aralkyloxy, C₇-C₃₂ alkylaryloxy, C₉-C₃₂ aralkenyloxy, and C₉-C₃₂ alkenylaryloxy;


R₃-R₆ are independently selected from the group consisting of H, OH, isosteres of OH; and

R₁ and R₇ are independently selected from the group consisting of C₁-C₂₅ alkyl, C₆-C₁₀ aryl, C₃-C₈ cycloalkyl, C₂-C₂₂ alkenyl, C₃-C₈ cycloalkenyl, C₇-C₃₂ aralkyl, C₇-C₃₂ alkylaryl, C₉-C₃₂ aralkenyl, and C₉-C₃₂ alkenylaryl;

with the provisos that (i) when X is O, Y is O or CH₂, and R₃ is H, at least one of R₂ and R₄-R₆ is not OH; (ii) when A is CH₂COOH or CH(COOH)₂, CHCOOH, or C(COOH)₂, X and Y cannot be simultaneously O; and (iii) all of R₂-R₆ are not simultaneously H.


2. (Original) The compound of claim 1, wherein A is P(O)OH.

3. (Currently Amended) The compound of claim 1 or 2, which has the formula Ia:



(Ia).

4. (Currently Amended) The compound of claim 1 or 2, which has the formula Ib:



(Ib).

5. (Currently Amended) The compound of ~~any of claims 2-4, claim 2~~, wherein X and Y are O.

6. (Currently Amended) The compound of ~~any of claims 1-5, claim 1~~, wherein R₁ is a C₁-C₂₅ alkyl.

7. (Currently Amended) The compound of ~~any of claims 1-6, claim 1~~, wherein R₁ is a C₁₀-C₂₅ alkyl.

8. (Currently Amended) The compound of ~~any of claims 1-7, claim 1~~, wherein R₁ is a C₁₅-C₂₀ alkyl.

9. (Currently Amended) The compound of ~~any of claims 1-8, claim 1~~, wherein R₁ is a C₁₈ alkyl.

10. (Currently Amended) The compound of ~~any of claims 1-9, claim 1~~, wherein R₇ is a C₁-C₂₅ alkyl.

11. (Currently Amended) The compound of ~~any of claims 1-10, claim 1~~, wherein R₇ is a C₁-C₁₅ alkyl.

12. (Currently Amended) The compound of ~~any of claims 1-11~~, claim 1, wherein R₇ is a C₁-C₅ alkyl.

13. (Currently Amended) The compound of ~~any of claims 1-12~~, claim 1, wherein R₇ is methyl.

14. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₂ is C₁-C₂₅ alkyloxy.

15. (Currently Amended) The compound of ~~any of claims 1-14~~, claim 1, wherein R₂ is C₁-C₁₅ alkyloxy.

16. (Currently Amended) The compound of ~~any of claims 1-15~~, claim 1, wherein R₂ is C₁-C₅ alkyloxy.

17. (Currently Amended) The compound of ~~any of claims 1-16~~, claim 1, wherein R₂ is methoxy.

18. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₂ is C₇-C₃₂ aralkyloxy.

19. (Currently Amended) The compound of ~~any of claims 1-13 and 18~~, claim 1, wherein R₂ is cyclohexylmethoxy.

20. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₂ is H.

21. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₃ is H.

22. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₄ is H.

23. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₅ is H.

24. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₆ is H.

25. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₂ and R₃ are H.

26. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₃ and R₄ are H.

27. (Currently Amended) The compound of ~~any of claims 1-13~~, claim 1, wherein R₅ and R₆ are H.

28. (Original) The compound of claim 3, wherein X and Y are O, R₁ is C₁₈H₃₇, and R₇ is methyl.

29. (Original) The compound of claim 28, wherein R₂ is methoxy, R₃ is H, and R₄-R₆ are OH.

30. (Original) The compound of claim 28, wherein R₂-R₃ are H and R₄-R₆ are OH.

31. (Original) The compound of claim 28, wherein R₂-R₃ and R₅-R₆ are OH and R₄ is H.

32. (Original) The compound of claim 28, wherein R₂ is i-butyloxy, R₃ is H, and R₄-R₆ are OH.

33. (Original) The compound of claim 28, wherein R₂ is cyclohexylmethoxy, R₃ is H, and R₄-R₆ are OH.

34. (Original) The compound of claim 28, wherein R₂-R₃ and R₆ are OH and R₄-R₅ are H.

35. (Original) The compound of claim 28, wherein R₂-R₄ and R₆ are OH and R₅ is H.

36. (Original) The compound of claim 28, wherein R₂, R₄, and R₆ are OH and R₃ and R₅ are H.

37. (Currently Amended) A pharmaceutical composition comprising a compound of ~~any of claims 1-36~~ claim 1 and a pharmaceutically acceptable carrier.

38. (Currently Amended) A method of preventing or treating a disease, or a condition that predisposes to a disease, which is characterized by the activation of the

serine/threonine kinase Akt in an animal comprising administering to the animal a preventive or treatment effective amount of a compound of ~~any of claims 1-36~~ claim 1.

39. (Original) The method of claim 38, wherein the disease is a cancer.

40. (Original) The method of claim 39, wherein the cancer is breast cancer, lung cancer, ovarian cancer, uterine cancer, brain cancer, sarcoma, melanoma, leukemia, lymphoma, colorectal cancer, prostate cancer, or liver cancer.

41. (Original) The method of claim 38, wherein the disease is a rheumatologic disease.

42. (Original) The method of claim 41, wherein the rheumatologic disease is rheumatoid arthritis or osteoarthritis.

43. (Original) The method of claim 38, wherein the disease is a pulmonary disease.

44. (Original) The method of claim 43, wherein the pulmonary disease is chronic obstructive pulmonary disease (COPD).

45. (Original) The method of claim 38, wherein the disease or condition is a precancerous lesion.

46. (Original) The method of claim 38, wherein the disease is a cardiovascular disease.

47. (Original) The method of claim 38, wherein the disease is a dermatologic disease.

48. (Original) The method of claim 38, wherein the disease is a gynecological disease.

49. (Original) The method of claim 38, wherein the disease is a vascular disease.

50. (Original) The method of claim 38, wherein the disease is a neurologic disease.

51. (Original) The method of claim 38, wherein the disease is an infectious disease.

52. (Original) The method of claim 38, wherein the infectious disease is a bacterial, viral, retroviral, or parasitic disease.

53. (Currently Amended) A method of increasing apoptosis of a cell comprising contacting the cell with a compound of ~~any of claims 1-36~~ claim 1.

54. (Currently Amended) A method for inhibiting PH domain binding comprising exposing a material containing an PH domain to a compound of ~~any of claims 1-36~~ claim 1.

55. (Currently Amended) A method for determining the presence of a PH domain in a material comprising:

- (a) exposing a sample of said material to a PH domain binding compound and obtaining a first binding result;
- (b) exposing another sample of said material to a compound of ~~any of claims 1-36~~ claim 1 and obtaining a second binding result; and
- (c) comparing the first and second binding results to determine whether a PH domain is present in the material.